Intra-Cellular Therapies Receives License From Bristol-Myers Squibb

Intra-Cellular Therapies (ITI), a privately held biopharmaceutical company focusing on the development of new therapeutics for neuropsychiatric and neurodegenerative disorders, announced that it has been granted an exclusive, worldwide license to a family of preclinical compounds from Bristol-Myers Squibb.

()a href="http://www.biospace.com/news_story.cfm?StoryID=20233420&full=1" target="_blank">BioSpace